Status:

COMPLETED

Oxytocin Administration During Cesarean Section

Lead Sponsor:

Assiut University

Conditions:

Postpartum Hemorrhage

Eligibility:

FEMALE

20-40 years

Phase:

PHASE4

Brief Summary

Cesarean delivery is defined as fetal birth through incisions in the abdominal wall and the uterine wall. This definition does not include removal of the fetus from the abdominal cavity in the case of...

Eligibility Criteria

Inclusion

  • Primigravida or multigravida
  • Term (37 - 42 weeks),
  • Singleton pregnancies
  • Booked for elective caesarean section.
  • Accepting to participate in the study.

Exclusion

  • • Medical disorders involving the heart, liver, kidney or brain.
  • Diabetes mellitus and hypertension.
  • Blood disorders (e.g. coagulopathies, thrombocytopenia)
  • Patients requiring blood transfusion due to anemia.
  • Risk factors for uterine atony e.g. macrosomia, polyhydramnios and multiple pregnancy.
  • Previous 2 or more cesarean section
  • Placenta previa or placental abruption
  • Previous major obstetric haemorrhage (\>1000 ml) in previous deliveries.
  • Known fibroid or adenomyosis.
  • Women who received anticoagulant therapy.
  • Severe preeclampsis.
  • Uterine anomalies.

Key Trial Info

Start Date :

October 1 2016

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2017

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT03344302

Start Date

October 1 2016

End Date

September 1 2017

Last Update

April 23 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Assiut Faculty of Medicine

Asyut, Egypt